The t(4;6)(q22;q15) occurs in 11.7% of patients.
The t(4;6)(q22;q15) is not independently associated with patient outcome. However, it occurs more frequently in high clinical T stage, high tumor volume specimens and in those with high baseline PSA (P=0.001, 0.001 and 0.01, respectively).
The t(4;6)(q22;q15) occurs more frequently in samples with two or more TMPRSS2:ERG fusion genes caused by internal deletion than in samples without these genomic alterations, but this correlation is not statistically significant (P=0.0628).
References
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer. Shan L, Ambroisine L, Clark J, Yáñez-Muñoz RJ, Fisher G, Kudahetti SC, Yang J, Kia S, Mao X, Fletcher A, Flohr P, Edwards S, Attard G, De-Bono J, Young BD, Foster CS, Reuter V, Moller H, Oliver TD, Berney DM, Scardino P, Cuzick J, Cooper CS, Lu YJ; Transatlantic Prostate Group. Prostate Cancer Prostatic Dis. 2010 Jun;13(2):117-25. PMID: #20177423#
